USD0.000æéå€ååŒÂ  (ET)
273.56MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
3.100å§å€
3.260é«å€
15.16Måºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
19.46äºæ³PER
--çŽè¿12ã¶æé
åœ
15.86%売買å転ç
5.370忥çµå€
2.810å®å€
34.43M売買代é
æå€±é¡æ ªäŸ¡åçç
0.90PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-47.61%ç·è³ç£å©çç
8.59052é±é«å€
3.59åºæ¥é«æ¯ç%
-127.30MçŽå©ç
95.60Mæ ªåŒæ°
-4.31421æ ªåœããå©çïŒEPSïŒ
1.77ããŒã¿å€
-76.73%èªå·±è³æ¬å©çç
3.53052é±å®å€
8.38%æ¯ãå¹
66.60%ç²å©çç
273.56MæäŸ¡ç·é¡
-2.82ãªã¹ã¯ãªã¿ãŒã³
3.89%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Myriad Genetics Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»çæ©åš & å忥çã§ã®é äœã¯199äž50äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããããŒã«ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯6.50ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§éåžžã«äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Myriad Genetics Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Myriad Genetics Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Myriad Genetics Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Zimmer Biomet Holdings Inc
ZBH
31
ææšî
ææš
売ã(3)
äžç«(1)
è²·ã(0)
ç§»åå¹³å
売ã(6)
äžç«(0)
è²·ã(0)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Myriad Genetics Incã®äŒæ¥æ
å ±î
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
äŒæ¥ã³ãŒãMYGN
äŒæ¥åMyriad Genetics Inc
æé«çµå¶è²¬ä»»è
ãCEOãRaha (Samraat S)
ãŠã§ããµã€ãhttps://myriad.com/
æ ªäž»çµ±èšî
ãããã質å
Myriad Genetics IncïŒMYGNïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îMyriad Genetics IncïŒMYGNïŒã®çŸåšã®æ ªäŸ¡ã¯2.86ã§ãã
Myriad Genetics Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îMyriad Genetics Incã®ãã£ãã«ãŒã·ã³ãã«ã¯MYGNã§ãã
Myriad Genetics Incã®52é±é«å€ã¯ãããã§ããïŒ
îMyriad Genetics Incã®52é±é«å€ã¯8.59ã§ãã
Myriad Genetics Incã®52é±å®å€ã¯ãããã§ããïŒ
îMyriad Genetics Incã®52é±å®å€ã¯3.53ã§ãã
Myriad Genetics Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îMyriad Genetics Incã®æäŸ¡ç·é¡ã¯273.42Mã§ãã
Myriad Genetics Inc (MYGN) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãMyriad Genetics IncïŒMYGNïŒã®ç·åè©äŸ¡ã¯signal_holdã§ãç®æšæ ªäŸ¡ã¯6.50ã§ãã
Myriad Genetics Inc (MYGN) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îMyriad Genetics IncïŒMYGNïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-3.95ã§ãã